Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Zydus Cadila
The generics industry struggled with the prior-year comparison as it saw an expected decline in revenues in the first quarter of 2021, driven by the global impact of the COVID-19 crisis. As a result, the performance of most companies fell short of the numbers reported in Q1 2020. However, a few managed to contradict the trend by reporting growth, either based on the launch of COVID-related drugs or performance in specific geographies.
Studies point to Johnson & Johnson, Pfizer and Bharat Biotech’s vaccines neutralizing the Delta variant of SARS-CoV-2, even if efficacy is lower compared to the original strain. This follows positive news from other vaccine companies but will the Lambda variant cause a setback?
Given its ever-growing role as a critical region for the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.
A plasmid DNA vaccine for human use has moved a step closer to reality, with Zydus Cadila applying for an accelerated nod for its COVID-19 candidate in India. 67% efficacy reported in an interim data readout and Delta variant being the prominent strain during a Phase III trial imply better odds for approval.
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- Cadila Healthcare
- Zydus Pharmaceuticals USA
- German Remedies
- Zynesher Pharmaceuticals USA LLC
- Nesher Pharmaceuticals Inc
- Quimica e Farmaceutica Nikkho do Brasil Ltda
- Bremer Pharma GmbH
- Nippon Universal Pharmaceuticals
- Zydus Discovery DMCC
- Zydus Urosciences
- Sentynl Therapeutics, Inc.